Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of haploidentical NK-cell adoptive immunotherapy versus cytarabine consolidation in high-risk acute myeloid leukemia
2013-003421-28Phase 2Terminated
- Sponsor
- Technische Universität Dresden
- Start
- Jan 2014
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of haploidentical natural killer cells in acute myeloid leukemia (AML) (2 arms), sponsored by Technische Universität Dresden. Primary endpoint: 2-year overall survival. Started Jan 2014; status: terminated.
02
Drugs
haploidentical natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2013-003421-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003421-28.